门冬氨酸钾镁治疗围产期心肌病的临床研究

Nmda Potassium Magnesium Clinical Research for the Treatment of Perinatal Cardiomyopathy

目的探讨一种对围产期心肌病患者、婴儿或胎儿均安全,疗效确切、有效的治疗措施。方法对住院期间确诊为围产期心肌病的患者进行随机分组,对照性研究分析。制定统一标准,收集有效实验数据,对有效数据进行统计学处理。结果治疗组可以显著降低肌酸激酶同工酶,症状缓解时间和住院时间均明显短于对照组,有显著性差异(P<0.05),但对于心功能(NYHA分级)、左心室舒张末期内径改善无显著性差异。结论门冬氨酸钾镁是治疗围产期心肌病的一种有效药物,不仅可以改善患者临床症状,有效降低心肌酶,还可以缩短住院日时间。

Objective To find a sense of perinatal cardiomyopathy patients, baby, or fetus are safety, efficacy, effective treatment measures. Methods During hospitalized in our hospital diagnosed as perinatal cardiomyopathy patients were randomized, controlled studies were analyzed. Formulate a unified standard, effective experimental data collection, statistical analysis was carried out on the valid data. Results The treatment group therapy effect is significantly better than the control group. Clinical symptoms improved time of treatment group was obviously shorter than the control group. And can significantly reduce the creatine kinase isoenzyme, shorten hospitalization time, the differences were statistically significant （P〈0,05）. But for cardiac function （NYHA classification）, left ventricular end-diastolic diameter to improve without statistical significance. Conclusion Nmda potassium magnesium is, perinatal cardiomyopathy is an effective drug treatment can not only improve the patients＇ clinical symptoms, reduce the myocardial enzyme, can also shorten the such confinement, reduce hospitalization costs.